From a prognostic point of view, the number of CTPC detected by NGF also proved to efficiently discriminate between MGUS cases with high (≥0.058 CTPC/μL) vs. low (<0.058 CTPC/μL) risk of progression to MM (median time to progression of 31 months vs. not reached, respectively), and to identify newly-diagnosed MM patients with reduced (≥0.1 CTPC/μL) vs. prolonged (<0.1 CTPC/μL) progression free survival (PFS) and overall survival (OS) (median PFS of 22 months vs. not reached and 75% OS of 17 months vs. not reached, respectively). The gene discussed is NGF; the disease is Miyoshi myopathy.